FDA Approves Neoadjuvant and Adjuvant Pembrolizumab for Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma By Ogkologos - July 18, 2025 608 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the KEYNOTE-689 study Source RELATED ARTICLESMORE FROM AUTHOR FX-909 Demonstrates Acceptable Safety and Preliminary Antitumour Activity, Establishing a Proof of Concept for PPARγ Inverse Agonism in Advanced Urothelial Cancer Pimicotinib Shows Robust Antitumour Activity and Clinically Meaningful Improvements in Patients with Tenosynovial Giant Cell Tumour FDA Grants Accelerated Approval to Zongertinib for Unresectable or Metastatic Non-Squamous NSCLC MOST POPULAR Targeted Therapy, Driven by Comprehensive Genomic Profiling and Molecular Tumour Board,... October 18, 2024 Distinct Patient, Tumour, Treatment Characteristics and a Different Pattern and Risk... March 10, 2025 Severe Immune-Related Gastroenterocolitis Described After in Utero Exposure to Pembrolizumab November 15, 2023 Breaking News: The Healthcare Marketplace Re-opens TODAY! February 15, 2021 Load more HOT NEWS Effects of Patient Navigation, Lower-Cost Drug Alternatives on the Cost of... Targeted Drug Erdafitinib Benefits Some Patients with Advanced Bladder Cancer FDA Approves Daratumumab and Hyaluronidase-fihj with Bortezomib, Lenalidomide, and Dexamethasone for... Second- or Third-Line Treatment with Tisotumab Vedotin Results in Greater Efficacy...
